Ascendis Pharma (ASND) Reiterated at Overweight by Cantor Fitzgerald After Model Update

April 1, 2026 7:03 AM

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating and $300.00 price target on Ascendis Pharma (NASDAQ: ASND).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found